Literature DB >> 24943391

Escitalopram efficacy in depression: a cross-ethnicity examination of the serotonin transporter promoter polymorphism.

Chad A Bousman1, Jerome Sarris, Eun-Soo Won, Hun-Soo Chang, Ajeet Singh, Hwa-Young Lee, Byung-Joo Ham, Chay-Hoon Tan, Min-Soo Lee, Chee H Ng.   

Abstract

Current evidence suggests that polymorphism in the serotonin transporter gene (5-HTTLPR) predicts antidepressant efficacy in whites but less so in Asians. However, it is not clear whether this effect can be observed for specific types of antidepressant drugs. White (n = 47) and Korean (n = 118) participants with major depressive disorder were treated with escitalopram and assessed over 8 weeks. Among those with the l/l but not l/s or s/s genotypes, whites had greater depression score reductions, response rates, and remission rates compared with Koreans. Our results suggest that 5-HTTLPR predicts escitalopram efficacy in an ethnicity-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24943391     DOI: 10.1097/JCP.0000000000000165

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  7 in total

Review 1.  Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.

Authors:  Chiara Fabbri; Alessandro Serretti
Journal:  Curr Psychiatry Rep       Date:  2015-07       Impact factor: 5.285

Review 2.  Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.

Authors:  Tristram A Lett; Henrik Walter; Eva J Brandl
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 3.  Precision medicine: does ethnicity information complement genotype-based prescribing decisions?

Authors:  Rashmi R Shah; Andrea Gaedigk
Journal:  Ther Adv Drug Saf       Date:  2017-12-01

4.  Associations between Serotonergic Genes and Escitalopram Treatment Responses in Patients with Depressive Disorder and Acute Coronary Syndrome: The EsDEPACS Study.

Authors:  Hee-Ju Kang; Kyung-Yeol Bae; Sung-Wan Kim; Il-Seon Shin; Young Joon Hong; Youngkeun Ahn; Myung Ho Jeong; Sung-Woo Park; Young-Hoon Kim; Jin-Sang Yoon; Jae-Min Kim
Journal:  Psychiatry Investig       Date:  2015-11-20       Impact factor: 2.505

5.  Paroxetine versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study.

Authors:  Young Sup Woo; Roger S McIntyre; Jung-Bum Kim; Min-Soo Lee; Jae-Min Kim; Hyeon Woo Yim; Tae-Youn Jun
Journal:  Clin Psychopharmacol Neurosci       Date:  2017-11-30       Impact factor: 2.582

6.  Dosage-related nature of escitalopram treatment-emergent mania/hypomania: a case series.

Authors:  Yasunari Yamaguchi; Sohei Kimoto; Takeshi Nagahama; Toshifumi Kishimoto
Journal:  Neuropsychiatr Dis Treat       Date:  2018-08-17       Impact factor: 2.570

Review 7.  Serotonin Transporter Genetic Variation and Antidepressant Response and Tolerability: A Systematic Review and Meta-Analysis.

Authors:  Kiera Stein; Abdullah Al Maruf; Daniel J Müller; Jeffrey R Bishop; Chad A Bousman
Journal:  J Pers Med       Date:  2021-12-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.